NEW YORK – Austrian firm OncoLab Diagnostics is developing a range of liquid biopsy-based diagnostic products, starting with an assay for monitoring for late-stage cancer recurrence.
OncoLab expects to receive a CE mark later this year for its RT-qPCR test, which detects and characterizes epithelial CTCs that express cytokeratin-19 (CK-19) as a biomarker. In addition, the firm is leveraging a recently signed partnership with Axon Dx to improve assay development.